Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.34 |
| ▸ | ATXN2 | Q99700 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3943283 | 0.94 | LMNA (0.38) | KMT2AMAPK1F10P2RX3 | |
| SCHEMBL3930885 | 0.92 | CREBBP (0.39) | CREBBPKMT2AF10KDM4EALDH1A1 | |
| SCHEMBL5856788 | 0.88 | CREBBP (0.39) | CREBBPKMT2AKDM4EALDH1A1ALPL | |
| SCHEMBL3937532 | 0.85 | LMNA (0.39) | CREBBPKMT2AF10ALPLP2RX3 | |
| SCHEMBL3942544 | 0.84 | KDM4E (0.38) | KMT2AMAPK1F10KDM4EALDH1A1 | |
| SCHEMBL3933359 | 0.83 | RET (0.42) | CREBBPF10P2RX3GAAMAPT | |
| SCHEMBL4494338 | 0.83 | MAPK1 (0.42) | MAPK1F10KDM4EALDH1A1MAPT | |
| SCHEMBL4497710 | 0.83 | MAPK1 (0.42) | MAPK1F10KDM4EALDH1A1MAPT | |
| SCHEMBL5857128 | 0.83 | MAPK1 (0.38) | KMT2AMAPK1F10KDM4EALDH1A1 | |
| SCHEMBL3937669 | 0.83 | MAPK1 (0.38) | KMT2AMAPK1F10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551830-B1 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7148249-B2 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | CREBBP 2532/4885KMT2A 1839/4885MAPK1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.